MINK1

MINK1 (MAP4K6) is a Ste20-family serine/threonine kinase that couples upstream signals — frequently reactive oxygen species — to substrate phosphorylation across immune, developmental, cytoskeletal, and cell-division programs (PMID:28400474, PMID:34480147). In innate immunity it directly phosphorylates NLRP3 at Ser725 through engagement of the NLRP3 LRR domain to prime inflammasome activation in macrophages, with ROS upregulating MINK1 activity, such that MINK1 loss blunts inflammatory responses in sepsis and peritonitis (PMID:34480147). In adaptive immunity ROS-activated MINK1 phosphorylates SMAD2 at Thr324 to inhibit TGF-β-induced SMAD2 activation and restrain Th17 differentiation, with MINK1-deficient mice showing exacerbated autoimmune encephalomyelitis (PMID:28400474); this same negative regulation of SMAD2 phosphorylation operates in chondrocytes (PMID:31647983). MINK1 also acts redundantly with MAP4K4 and TNIK as an upstream activator of DLK/JNK signaling in neurons, controlling DLK stabilization, c-Jun phosphorylation, and retrograde injury signaling (PMID:28993483). In Wnt/planar cell polarity signaling it phosphorylates Prickle on a conserved threonine to direct Rab5-dependent endosomal trafficking and membrane accumulation (PMID:22037766), and through phosphorylation of LL5β (PHLDB2) it promotes CLASP recruitment, PRICKLE1–LL5β complex assembly, focal adhesion disassembly, and cell migration (PMID:35971817). MINK1 phosphorylates the glucocorticoid receptor at Thr524 to recruit 14-3-3ζ to its ligand-binding domain (PMID:33744286), and it is a STRIPAK-complex component that binds STRN4 — whose associated PP2A downregulates MINK1 kinase activity — with MINK1 being required to complete cytokinesis at abscission (PMID:22665485). A de novo balanced translocation reducing MINK1 expression has been described as a candidate monogenic basis for autism, epilepsy, and osteoporosis (PMID:36012658).

1. 2004 Low

   Before functional characterization, the question was what protein architecture and interaction surfaces MINK1 presents; domain dissection defined a kinase domain, coiled-coil, proline-rich region, and GCK domain with interactors implicating cytoskeleton, cell cycle, and apoptosis.

   Evidence Computational fold recognition and yeast two-hybrid screening of coiled-coil and proline-rich domains

   PMID:15032605

   Open questions at the time

   • Interactions predicted but not biochemically validated
   • No catalytic substrate identified
   • Functional roles inferred only from interactor identity
2. 2011 High

   Establishing MINK1 as a direct kinase in a defined pathway, it was shown to phosphorylate Prickle on a conserved threonine to govern Rab5-dependent endosomal trafficking in Wnt/PCP signaling.

   Evidence Mass spectrometry, in vitro kinase assay, and genetic interaction in Drosophila and Xenopus

   PMID:22037766

   Open questions at the time

   • Phosphosite residue not mapped to a specific number
   • Mechanism linking phosphorylation to trafficking incomplete
   • Mammalian PCP relevance not addressed
3. 2012 High

   To place MINK1 in a regulatory complex and the cell cycle, it was identified as a STRIPAK subunit bound to STRN4 whose PP2A activity suppresses MINK1, and required for abscission-stage cytokinesis.

   Evidence STRIPAK mass spectrometry, co-immunoprecipitation, and siRNA with time-lapse microscopy

   PMID:22665485

   Open questions at the time

   • Cytokinesis substrate of MINK1 not identified
   • Mechanism of PP2A-mediated MINK1 inactivation unresolved
4. 2015 High

   Addressing MINK1 in vivo physiology, knockout mice revealed an essential role in platelet function, hemostasis, and thrombosis tied to impaired ADP secretion and reduced ERK/p38/Akt signaling.

   Evidence Knockout mice with bleeding, thrombosis, aggregation, and spreading assays

   PMID:26598717

   Open questions at the time

   • Direct platelet substrate of MINK1 not defined
   • Connection between MINK1 and the ERK/p38/Akt readouts mechanistically unmapped
5. 2017 High

   Two studies defined MINK1 as a ROS-responsive negative regulator of immunity, directly phosphorylating SMAD2 at Thr324 to limit Th17 differentiation, and as a redundant upstream activator of neuronal DLK/JNK signaling.

   Evidence Direct phosphorylation assays, knockout mice, EAE model, and DRG neuron knockdown/inhibition with DLK and c-Jun readouts

   PMID:28400474 PMID:28993483

   Open questions at the time

   • Mechanism of ROS sensing by MINK1 not resolved
   • Redundancy with MAP4K4/TNIK obscures individual neuronal contribution
   • Direct DLK substrate relationship not established
6. 2021 High

   MINK1 was shown to phosphorylate NLRP3 at Ser725 via the LRR domain to prime inflammasome activation, and to phosphorylate the glucocorticoid receptor at Thr524 to recruit 14-3-3ζ, broadening its direct-substrate repertoire.

   Evidence In vitro kinase assays, domain-mapped co-IP, knockout sepsis/peritonitis models, kinase screen, and X-ray crystallography of 14-3-3ζ with phospho-GR peptide

   PMID:33744286 PMID:34480147

   Open questions at the time

   • Upstream activation of MINK1 in macrophages partially defined (ROS) but signaling input unclear
   • Functional consequence of GR Thr524 phosphorylation on transcription not fully characterized
7. 2022 Medium

   Expanding MINK1's cytoskeletal and oncogenic roles, it was found to phosphorylate LL5β to drive focal adhesion disassembly and migration, to suppress p53 via AKT/MDM2 conferring chemoresistance, and to regulate canonical Wnt fate decisions through the downstream target Hmga2.

   Evidence Phosphoproteomics, kinase-inhibitor and migration assays, CRISPR kinome screen with phospho-array and xenografts, and Xenopus loss-of-function with proteomics and Hmga2 rescue

   PMID:35971817 PMID:36182968 PMID:36572140

   Open questions at the time

   • Whether MINK1 directly phosphorylates AKT pathway components or acts indirectly is unresolved
   • Hmga2 regulation mechanism downstream of MINK1 not defined
   • Single-lab findings per role
8. 2022 Low

   A candidate human disease link emerged from a de novo translocation reducing MINK1 expression, implicating haploinsufficiency in autism, epilepsy, and osteoporosis.

   Evidence Long-read genome sequencing, optical mapping, and transcriptomics of patient iPSC-derived neuroepithelial cells

   PMID:36012658

   Open questions at the time

   • Single patient with pathway analysis only
   • No mechanistic experiment linking MINK1 loss to the neural phenotypes
   • Causality versus correlation not established
9. 2024 Low

   MINK1's inflammasome and degenerative roles were extended to intervertebral disc degeneration, where deficiency triggers NF-κB-driven NP cell pyroptosis, with direct NLRP3-domain interaction shown only in a fish ortholog.

   Evidence Knockout mouse IVD degeneration models with NF-κB analysis and CcMINK1–CcNLRP3 co-IP in common carp

   PMID:38723371

   Open questions at the time

   • Mammalian direct NLRP3 interaction not demonstrated here
   • Mechanistic data restricted to fish ortholog
   • Phenotypic mammalian data only
10. 2025 Medium

    A regulatory axis upstream of MINK1 was defined in which miR-17-5p directly targets MINK1, and MINK1 activates JNK/c-Jun to upregulate ULBP2 and enhance NK cytotoxicity against breast cancer cells.

    Evidence Dual-luciferase reporter, MINK1 knockdown/overexpression with JNK inhibition, flow cytometry, and in vivo NK cytotoxicity

    PMID:39963142

    Open questions at the time

    • Direct MINK1 substrate in JNK activation not identified
    • Generalizability beyond breast cancer context unknown

• How MINK1 substrate selection is governed across its diverse contexts — and how a single ROS-activated kinase is partitioned between inflammasome priming, SMAD2 inhibition, DLK/JNK activation, PCP trafficking, and cytokinesis — remains unresolved.
• No unifying model of context-specific substrate targeting
• STRIPAK/PP2A regulation not integrated with the various effector pathways
• Direct human disease causation unconfirmed